Central Trust Company’s Amedisys AMED Stock Holding History

Central Trust Company’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13	Closed	-$1.28K	–	1413
2025 Q2	$1.28K	Hold	13	–	–	﹤0.01%	1354
2025 Q1	$1.21K	Hold	13	–	–	﹤0.01%	1365
2024 Q4	$1.18K	Hold	13	–	–	﹤0.01%	1369
2024 Q3	$1.25K	Hold	13	–	–	﹤0.01%	1295
2024 Q2	$1.19K	Sell	13 -11	-46%	-$1.02K	﹤0.01%	1323
2024 Q1	$2.21K	Hold	24	–	–	﹤0.01%	1266
2023 Q4	$2.28K	Buy	24 +11	+85%	+$1.03K	﹤0.01%	1270
2023 Q3	$1.22K	Buy	+13	New	+$1.2K	﹤0.01%	1297

Other funds holding AMED

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

MCI

MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Central Trust Company's AMED Position: Q3 2025 in Review

Central Trust Company sold out of Amedisys (AMED) in Q3 2025, closing a stake of 13 shares — an estimated $1.28K sold.

Central Trust Company first reported a position in AMED in Q3 2023 and held it in 8 quarters. The position peaked at $2.28K in Q4 2023. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

Central Trust Company reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
Central Trust Company sold 13 Amedisys shares in Q3 2025, an estimated $1.28K.
Central Trust Company first reported a position in Amedisys in Q3 2023 and held it in 8 quarters.
Central Trust Company's Amedisys position peaked at $2.28K in Q4 2023.
4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Central Trust Company's 13F filing for Q3 2025, filed 6 Nov 2025.